Given that NRP1 serves as a crucial factor for SARS-CoV-2 infection and facilitates the virus’s entry into cells, the researchers have advocated for the potential use of NRP1 inhibitors, such as pegaptanib, as therapeutic agents in specific types of cancer, particularly lung and genitourinary cancers, in patients who have experienced COVID-19 [260]. The gene discussed is NRP1; the disease is urogenital neoplasm.